Cargando…
A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials
BACKGROUND: Constipation is a common side effect of antimuscarinic treatment for overactive bladder (OAB). This review evaluates the incidence and impact of constipation on the lives of patients with OAB being treated with darifenacin. METHODS: Constipation data from published Phase III and Phase II...
Autores principales: | Tack, Jan, Wyndaele, Jean-Jacques, Ligozio, Greg, Egermark, Mathias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468023/ https://www.ncbi.nlm.nih.gov/pubmed/23055780 http://dx.doi.org/10.2147/DHPS.S26580 |
Ejemplares similares
-
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008) -
Darifenacin hydrobromide
por: Selvanayagam, S., et al.
Publicado: (2009) -
A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder
por: Chancellor, M B, et al.
Publicado: (2008) -
Treatment of overactive bladder in the aging population: focus on darifenacin
por: Jha, Swati, et al.
Publicado: (2006) -
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)